In SS patient 22 (P22), we found that SREBP and FASN inhibitors restricted cell proliferation, especially when both targets were co-inhibited, with malignant cells (defined as CD3+CD4+CD8-TCRvb+) being more sensitive than non-malignant CD4+ T cells (defined as CD3+CD4+CD8-TCRvb-) (Figure 6A–C). This evidence concerns the gene FASN and synovial sarcoma.